Background
kidney damage, autosomal dominant polycystic kidney disease, ADPKD
ADPKD, PROGRESSION, AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). Progression during childhood could be treated before irreversible kidney damage occurs, but trial data are lacking. We evaluated the safety and efficacy of tolvaptan in children/adolescents with ADPKD.